Ads
related to: multiple myeloma- Contact a Representative
For Questions and Information
About This Treatment
- Phase 3 Trial
Explore the Phase 3 Trial Design,
Results, and Patient Population
- Primary and Subgroup Data
Primary- and Subgroup-
Specific Data
- Patient Profile
Potential Treatment Candidates
HCPs, See Who May Be Appropriate
- Contact a Representative
Search results
GSK blood cancer drug nearly halves risk of death in late-stage trial | Honolulu Star-Advertiser
Honolulu Star-Advertiser· 3 days agoGSK’s multiple myeloma drug Blenrep nearly halved the risk of disease progression or death compared...
Advances in CAR T-Cell Therapy for Multiple Myeloma
MedPage Today· 5 days agoB-cell maturation antigen (BCMA)-directed CAR T-cell therapies are now established options for treating multiple myeloma after relapse, but efforts are...
EXCLUSIVE: Telo Genomics' Smoldering Multiple Myeloma Prognostic Test Predicts Risk Of Disease...
Benzinga via Yahoo Finance· 6 days agoOn Thursday, Telo Genomics Corp (OTC:TDSGF) announced that the manuscript “Three-dimensional...
TECVAYLI® (teclistamab-cqyv) shows sustained deep and durable responses in patients with relapsed or...
Forrest City Times-Herald· 2 days ago"With the longest follow-up of any bispecific antibody, teclistamab demonstrates continued deep and durable responses observed in patients with relapsed or refractory multiple
...Johnson At ASCO Highlights Long Term Data From Multiple Myeloma Drug, Shows Sustained Deep,...
Benzinga via Yahoo Finance· 2 days agoMonday, Johnson & Johnson (NYSE:JNJ) announced longer-term data from Phase 1/2 MajesTEC-1 study of...
GSK blood cancer drug nearly halves risk of death in late-stage trial
AOL· 3 days agoGSK's multiple myeloma drug Blenrep nearly halved the risk of disease progression or death compared to standard-of-care treatments for the incurable blood ...
EXCLUSIVE: Telo Genomics' Smoldering Multiple Myeloma Prognostic Test Predicts Risk Of Disease...
Benzinga· 6 days agoAmerican Journal of Hematology accepts Telo Genomics' study on TeloViewSMM, a prognostic test for smoldering multiple myeloma. The test showed 85% positive ...
GSK builds case for return of multiple myeloma drug Blenrep
BioPharma Dive via Yahoo Finance· 3 days agoStudy results showed the antibody-drug conjugate helped stave off disease progression better than a...
...Johnson At ASCO Highlights Long Term Data From Multiple Myeloma Drug, Shows Sustained Deep,...
Benzinga· 2 days agoResults from the MajesTEC-1 study show that, at a median follow-up of 30.4 months, patients treated...
Blenrep-Based Regimen Yields PFS Benefit in Relapsed/Refractory Myeloma
MedPage Today· 3 days agoAt a median follow-up of 21.8 months, the 12-month estimated PFS rates were 71% with BPd versus 51%...
Ad
related to: multiple myeloma